Kosi–Trebotic L, et al. – This trial incorporated the analysis of sex–specific variations of Dipeptidyl peptidase–four (DPP–4) inhibitor effects on hepatic (HCL) and myocardial fat content (MYCL), in type 2 diabetic patients Gliptins and cardiometabolic risk. A marked decrease of HCL, MYCL and weight loss was noted particularly in women, after 6 months of DPP–4–therapy. Hence, gliptins served as a feasible therapeutic option in fatty liver patients with diabetes, potentially including positive effects on cardiovascular function, especially in women.